Press / Medias
Christensenella: the key to unlocking gut microbiome-based drug discovery?
Jan 2, 2019
LNC Therapeutics recently signed an exclusive license agreement with Cornell University for its Christensenella patent, which covers a recently discovered family of gut bacteria considered to have the potential to unlock a wide range of therapeutic applications for conditions such as obesity and other metabolic diseases. Will this form the foundation for the first drugs using microbiome bacteria? Sally Turner finds out.
In the same category
Press / Medias
Press / Medias
Seventure Partners : Une croissance continue dans le secteur du microbiome en 2021 qui va se...
Mar 15, 2022
more +
Press / Medias